SRNE — Sorrento Therapeutics Share Price
0.000.00%
Last trade - 00:00- $4.80m
- $73.42m
- $62.84m
- 14
- 55
- 11
- 17
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.08 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -246.26% | ||
| Return on Equity | n/a | ||
| Operating Margin | -734.68% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 21.19 | 31.43 | 39.99 | 52.9 | 62.84 | 57.53 | 210.65 | -16.18% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.
Directors
- Henry Ji CHM (56)
- Dorman Followwill LED (57)
- Kim Janda DRC (63)
- Jaisim Shah DRC (59)
- David Lemus IND (58)
- Robin Smith IND (56)
- Yue Wu IND (57)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- December 4th, 2009
- Public Since
- January 19th, 2007
- No. of Shareholders
- 197
- No. of Employees
- 949
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 551,281,154
- Address
- 4955 Directors Place, SAN DIEGO, 92121
- Web
- https://sorrentotherapeutics.com/
- Phone
- +1 8582034100
- Auditors
- Ernst & Young LLP
Upcoming Events for SRNE
Q2 2024 Sorrento Therapeutics Inc Earnings Release
Similar to SRNE
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Sorrento Therapeutics share price?
As of Today at 23:23 UTC, shares in Sorrento Therapeutics are trading at $0.01. This share price information is delayed by 15 minutes.
How has the Sorrento Therapeutics share price performed this year?
Shares in Sorrento Therapeutics last closed at $0.01 and the price had moved by -97.26% over the past 365 days. In terms of relative price strength the Sorrento Therapeutics share price has underperformed the S&P500 Index by -97.7% over the past year.
What are the analyst and broker recommendations for Sorrento Therapeutics?
The overall consensus recommendation for Sorrento Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Sorrento Therapeutics dividend yield?
Sorrento Therapeutics does not currently pay a dividend.
Does Sorrento Therapeutics pay a dividend?
Sorrento Therapeutics does not currently pay a dividend.
When does Sorrento Therapeutics next pay dividends?
Sorrento Therapeutics does not currently pay a dividend.
How do I buy Sorrento Therapeutics shares?
To buy shares in Sorrento Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sorrento Therapeutics?
As of the previous close price of $0.01, shares in Sorrento Therapeutics had a market capitalisation of $5.24m.
Where are Sorrento Therapeutics shares listed?
Here are the trading details for Sorrento Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: SRNE
What kind of share is Sorrento Therapeutics?
Based on an overall assessment of its quality, value and momentum Sorrento Therapeutics is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sorrento Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Sorrento Therapeutics is $13.00. That is 136742.11% above the last closing price of $0.01.
Analysts covering Sorrento Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.68 for the next financial year.
What is the trend in the Sorrento Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sorrento Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -94.18%.
As of the last closing price of $0.01, shares in Sorrento Therapeutics were trading -82.7% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sorrento Therapeutics PE Ratio?
The Sorrento Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sorrento Therapeutics?
Sorrento Therapeutics' management team is headed by:
- Henry Ji - CHM
- Dorman Followwill - LED
- Kim Janda - DRC
- Jaisim Shah - DRC
- David Lemus - IND
- Robin Smith - IND
- Yue Wu - IND